September 8, 2022
AstraZeneca Pharmaceuticals: Latest Data on Management of Factor Xa Inhibitor-Related Acute Major Bleeding
Tuesday, October 10
2:30 pm – 3:15 pm
Location: Expert Theater 2
Latha Ganti, MD, MS, MBA, FACEP
- Recognize the impact of apixaban- and rivaroxaban-related major bleeding.
- Review a reversal agent that restores FXa activity and thrombin generation in patients with apixaban- and rivaroxaban-related acute major bleeding.
- Discuss clinical trial and real-world evidence of this reversal agent for apixaban- and rivaroxaban-related major bleeding.
Supported by AstraZeneca